Should we embrace or ablate our urge to (ovarian) suppress?

J Clin Oncol. 2014 Dec 10;32(35):3920-2. doi: 10.1200/JCO.2014.57.9953. Epub 2014 Nov 3.

Authors

Rachel C Jankowitz¹, Shannon Puhalla¹, Nancy E Davidson²

Affiliations

¹ University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA.
² University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA davidsonne@upmc.edu.

PMID: 25366692
DOI: 10.1200/JCO.2014.57.9953

No abstract available

Publication types

Editorial
Comment

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology*
Female
Humans
Ovary / drug effects*
Tamoxifen / administration & dosage*

Substances

Tamoxifen